|
2025-03-28 |
2025-03-26 |
B
Purchase
|
Brown Melinda
Non-Executive Director
|
1,839
+25.5%
4.75
USD 8,735
|
1,839
+25.5%
|
4.75
|
USD 8,735
|
|
|
2025-03-28 |
2025-03-26 |
B
Purchase
|
Buehler Kevin
Non-Executive Director
|
4,523
+51.9%
4.67
USD 21,122
|
4,523
+51.9%
|
4.67
|
USD 21,122
|
|
|
2025-03-27 |
2025-03-25 |
B
Purchase
|
Germano Geno J
Non-Executive Director
|
3,250
+41.6%
5.30
USD 17,225
|
3,250
+41.6%
|
5.30
|
USD 17,225
|
|
|
2025-03-25 |
2025-03-24 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
964
-0.9%
5.56
USD 5,360
|
964
-0.9%
|
5.56
|
USD 5,360
|
|
|
2025-03-05 |
2025-03-04 |
PS
Planned sale
|
SMITH J. JEFFERSON
Chief Research Officer
Officer
|
154
-0.2%
4.91
USD 756
|
154
-0.2%
|
4.91
|
USD 756
|
|
|
2025-03-05 |
2025-03-04 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
272
-1.1%
4.91
USD 1,336
|
272
-1.1%
|
4.91
|
USD 1,336
|
|
|
2025-01-22 |
2025-01-22 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
8,928
-26.8%
4.79
USD 42,765
|
8,928
-26.8%
|
4.79
|
USD 42,765
|
|
|
2025-01-22 |
2025-01-22 |
PS
Planned sale
|
SMITH J. JEFFERSON
Chief Research Officer
Officer
|
10,287
-10.5%
4.79
USD 49,275
|
10,287
-10.5%
|
4.79
|
USD 49,275
|
|
|
2025-01-22 |
2025-01-21 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
36,838
-25.6%
4.67
USD 172,033
|
36,838
-25.6%
|
4.67
|
USD 172,033
|
|
|
2025-01-02 |
2024-12-30 |
B
Purchase
|
Germano Geno J
Non-Executive Director
|
3,605
+85.8%
4.49
USD 16,186
|
3,605
+85.8%
|
4.49
|
USD 16,186
|
|
|
2024-12-31 |
2024-12-27 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
2,113
+5.5%
4.75
USD 10,037
|
2,113
+5.5%
|
4.75
|
USD 10,037
|
|
|
2024-12-31 |
2024-12-27 |
B
Purchase
|
Buehler Kevin
Non-Executive Director
|
4,320
+98.4%
4.88
USD 21,082
|
4,320
+98.4%
|
4.88
|
USD 21,082
|
|
|
2024-12-30 |
2024-12-26 |
B
Purchase
|
Brown Melinda
Non-Executive Director
|
3,016
+71.8%
4.55
USD 13,723
|
3,016
+71.8%
|
4.55
|
USD 13,723
|
|
|
2024-11-21 |
2024-11-21 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
3,000
+8.6%
6.76
USD 20,280
|
3,000
+8.6%
|
6.76
|
USD 20,280
|
|
|
2024-11-05 |
2024-11-04 |
S
Sale
|
Amoroso Michael
President and CEO
Executive Director
|
3,012
-9.5%
8.19
USD 24,668
|
3,012
-9.5%
|
8.19
|
USD 24,668
|
|
|
2024-11-05 |
2024-11-04 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
588
-6.9%
8.19
USD 4,816
|
588
-6.9%
|
8.19
|
USD 4,816
|
|
|
2024-06-11 |
2024-06-10 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
93
-1.4%
11.79
USD 1,096
|
93
-1.4%
|
11.79
|
USD 1,096
|
|
|
2024-06-11 |
2024-06-10 |
S
Sale
|
SMITH J. JEFFERSON
Chief Research Officer
Officer
|
50
-0.1%
11.79
USD 590
|
50
-0.1%
|
11.79
|
USD 590
|
|
|
2024-05-03 |
2024-05-02 |
PS
Planned sale
|
List Alan
Chief Medical Officer
Officer
|
290
-6.1%
10.32
USD 2,993
|
290
-6.1%
|
10.32
|
USD 2,993
|
|
|
2024-05-03 |
2024-05-02 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
272
-4.6%
10.32
USD 2,807
|
272
-4.6%
|
10.32
|
USD 2,807
|
|
|
2024-05-03 |
2024-05-02 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
272
-4.6%
10.32
USD 2,807
|
272
-4.6%
|
10.32
|
USD 2,807
|
|
|
2024-05-03 |
2024-05-02 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
1,526
-10.0%
10.32
USD 15,748
|
1,526
-10.0%
|
10.32
|
USD 15,748
|
|
|
2024-05-03 |
2024-05-02 |
S
Sale
|
SMITH J. JEFFERSON
Chief Research Officer
Officer
|
154
-0.2%
10.32
USD 1,589
|
154
-0.2%
|
10.32
|
USD 1,589
|
|
|
2024-04-30 |
2024-04-30 |
PS
Planned sale
|
List Alan
Chief Medical Officer
Officer
|
238
-5.9%
10.03
USD 2,386
|
238
-5.9%
|
10.03
|
USD 2,386
|
|
|
2024-01-23 |
2024-01-23 |
S
Sale
|
SMITH J. JEFFERSON
Chief Research Officer
Officer
|
28,000
-1.4%
0.37
USD 10,360
|
28,000
-1.4%
|
0.37
|
USD 10,360
|
|
|
2024-01-23 |
2024-01-22 |
PS
Planned sale
|
List Alan
Chief Medical Officer
Officer
|
21,526
-18.5%
0.36
USD 7,749
|
21,526
-18.5%
|
0.36
|
USD 7,749
|
|
|
2024-01-23 |
2024-01-22 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
137,390
-27.8%
0.36
USD 49,460
|
137,390
-27.8%
|
0.36
|
USD 49,460
|
|
|
2024-01-23 |
2024-01-22 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
21,287
-12.4%
0.36
USD 7,663
|
21,287
-12.4%
|
0.36
|
USD 7,663
|
|
|
2023-11-06 |
2023-11-03 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
16,023
-12.4%
0.40
USD 6,409
|
16,023
-12.4%
|
0.40
|
USD 6,409
|
|
|
2023-11-06 |
2023-11-03 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
125,025
-35.5%
0.40
USD 50,010
|
125,025
-35.5%
|
0.40
|
USD 50,010
|
|
|
2023-06-09 |
2023-06-08 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
13,361
-16.3%
0.75
USD 10,021
|
13,361
-16.3%
|
0.75
|
USD 10,021
|
|
|
2023-04-28 |
2023-04-27 |
PS
Planned sale
|
List Alan
Chief Medical Officer
Officer
|
7,771
-12.1%
0.79
USD 6,139
|
7,771
-12.1%
|
0.79
|
USD 6,139
|
|
|
2023-03-23 |
2023-03-22 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
46,999
-40.6%
0.82
USD 38,539
|
46,999
-40.6%
|
0.82
|
USD 38,539
|
|
|
2023-03-21 |
2023-03-17 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
20,000
+8.9%
0.86
USD 17,200
|
20,000
+8.9%
|
0.86
|
USD 17,200
|
|
|
2023-03-07 |
2023-03-06 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
12,172
-19.6%
1.07
USD 13,024
|
12,172
-19.6%
|
1.07
|
USD 13,024
|
|
|
2023-03-07 |
2023-03-06 |
PS
Planned sale
|
List Alan
Chief Medical Officer
Officer
|
9,473
-19.9%
1.07
USD 10,136
|
9,473
-19.9%
|
1.07
|
USD 10,136
|
|
|
2022-10-18 |
2022-10-17 |
PS
Planned sale
|
Amoroso Michael
President and CEO
Executive Director
|
11,006
-45.5%
1.32
USD 14,528
|
11,006
-45.5%
|
1.32
|
USD 14,528
|
|
|
2022-09-26 |
2022-09-23 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
8,200
+5.3%
1.23
USD 10,086
|
8,200
+5.3%
|
1.23
|
USD 10,086
|
|
|
2022-09-26 |
2022-09-22 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
37,037
+31.5%
1.34
USD 49,630
|
37,037
+31.5%
|
1.34
|
USD 49,630
|
|
|
2022-06-24 |
2022-06-22 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
33,784
+40.3%
1.50
USD 50,676
|
33,784
+40.3%
|
1.50
|
USD 50,676
|
|
|
2022-06-09 |
2022-06-08 |
PS
Planned sale
|
Scimeca Dario
General Counsel and Secretary
Officer
|
9,833
-23.2%
2.06
USD 20,256
|
9,833
-23.2%
|
2.06
|
USD 20,256
|
|
|
2022-06-09 |
2022-06-08 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
18,849
-0.5%
2.06
USD 38,829
|
18,849
-0.5%
|
2.06
|
USD 38,829
|
|
|
2022-04-28 |
2022-04-27 |
PS
Planned sale
|
List Alan
Chief Medical Officer
Officer
|
7,775
-29.9%
2.10
USD 16,328
|
7,775
-29.9%
|
2.10
|
USD 16,328
|
|
|
2022-03-21 |
2022-03-17 |
B
Purchase
|
Kelly John Alexander
Chief Financial Officer
Officer
|
16,677
+85.5%
3.08
USD 51,365
|
16,677
+85.5%
|
3.08
|
USD 51,365
|
|
|
2021-06-25 |
2021-06-23 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
30,000
-21.2%
10.65
USD 319,500
|
30,000
-21.2%
|
10.65
|
USD 319,500
|
|
|
2021-06-23 |
2021-06-21 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
15,000
-11.9%
10.77
USD 161,550
|
15,000
-11.9%
|
10.77
|
USD 161,550
|
|
|
2021-06-21 |
2021-06-18 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
10,000
-8.2%
11.00
USD 110,000
|
10,000
-8.2%
|
11.00
|
USD 110,000
|
|
|
2021-06-21 |
2021-06-17 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
10,000
-8.2%
10.44
USD 104,400
|
10,000
-8.2%
|
10.44
|
USD 104,400
|
|
|
2021-06-16 |
2021-06-15 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
2,858
-2.5%
11.20
USD 32,010
|
2,858
-2.5%
|
11.20
|
USD 32,010
|
|
|
2021-06-15 |
2021-06-11 |
S
Sale
|
THOMSON DAVID S.
Chief Operating Officer
Officer
|
30,000
-21.2%
11.52
USD 345,600
|
30,000
-21.2%
|
11.52
|
USD 345,600
|
|
|
2021-05-19 |
2021-05-17 |
S
Sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
20,000
-0.5%
9.38
USD 187,600
|
20,000
-0.5%
|
9.38
|
USD 187,600
|
|
|
2021-05-18 |
2021-05-14 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,673
-0.2%
9.17
USD 88,701
|
9,673
-0.2%
|
9.17
|
USD 88,701
|
|
|
2021-05-14 |
2021-05-13 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,675
-0.5%
8.96
USD 86,688
|
9,675
-0.5%
|
8.96
|
USD 86,688
|
|
|
2021-05-14 |
2021-05-13 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,673
-0.2%
9.15
USD 88,508
|
9,673
-0.2%
|
9.15
|
USD 88,508
|
|
|
2021-05-14 |
2021-05-12 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,676
-0.2%
8.72
USD 84,375
|
9,676
-0.2%
|
8.72
|
USD 84,375
|
|
|
2021-05-11 |
2021-05-10 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,746
-0.5%
8.25
USD 80,405
|
9,746
-0.5%
|
8.25
|
USD 80,405
|
|
|
2021-05-11 |
2021-05-07 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,742
-0.5%
8.57
USD 83,489
|
9,742
-0.5%
|
8.57
|
USD 83,489
|
|
|
2021-04-21 |
2021-04-19 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,676
-0.2%
8.69
USD 84,084
|
9,676
-0.2%
|
8.69
|
USD 84,084
|
|
|
2021-04-19 |
2021-04-16 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,675
-0.2%
8.84
USD 85,527
|
9,675
-0.2%
|
8.84
|
USD 85,527
|
|
|
2021-04-19 |
2021-04-15 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,676
-0.2%
8.76
USD 84,762
|
9,676
-0.2%
|
8.76
|
USD 84,762
|
|
|
2021-03-22 |
2021-03-18 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,665
-0.2%
11.08
USD 107,088
|
9,665
-0.2%
|
11.08
|
USD 107,088
|
|
|
2021-03-18 |
2021-03-17 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,665
-0.2%
10.92
USD 105,542
|
9,665
-0.2%
|
10.92
|
USD 105,542
|
|
|
2021-03-18 |
2021-03-16 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,661
-0.2%
11.97
USD 115,642
|
9,661
-0.2%
|
11.97
|
USD 115,642
|
|
|
2021-03-16 |
2021-03-12 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,712
-0.5%
11.36
USD 110,328
|
9,712
-0.5%
|
11.36
|
USD 110,328
|
|
|
2021-03-12 |
2021-03-11 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,711
-0.5%
11.38
USD 110,511
|
9,711
-0.5%
|
11.38
|
USD 110,511
|
|
|
2021-03-12 |
2021-03-10 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,710
-0.5%
11.79
USD 114,481
|
9,710
-0.5%
|
11.79
|
USD 114,481
|
|
|
2021-02-24 |
2021-02-22 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,660
-0.2%
12.04
USD 116,306
|
9,660
-0.2%
|
12.04
|
USD 116,306
|
|
|
2021-02-22 |
2021-02-19 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
9,663
-0.2%
11.55
USD 111,608
|
9,663
-0.2%
|
11.55
|
USD 111,608
|
|
|
2021-02-22 |
2021-02-18 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
6,871
-0.2%
12.20
USD 83,826
|
6,871
-0.2%
|
12.20
|
USD 83,826
|
|
|
2021-02-22 |
2021-02-18 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,705
-0.5%
12.23
USD 118,692
|
9,705
-0.5%
|
12.23
|
USD 118,692
|
|
|
2021-02-18 |
2021-02-17 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,705
-0.5%
12.28
USD 119,177
|
9,705
-0.5%
|
12.28
|
USD 119,177
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
KANE MATTHEW R.
President and CEO
Executive Director
|
9,697
-0.5%
13.30
USD 128,970
|
9,697
-0.5%
|
13.30
|
USD 128,970
|
|
|
2021-02-02 |
2021-01-29 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
6,444
-0.2%
12.25
USD 78,939
|
6,444
-0.2%
|
12.25
|
USD 78,939
|
|
|
2021-01-29 |
2021-01-28 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
6,444
-0.2%
11.97
USD 77,135
|
6,444
-0.2%
|
11.97
|
USD 77,135
|
|
|
2021-01-29 |
2021-01-27 |
PS
Planned sale
|
JANTZ DEREK
Chief Scientific Officer
Executive Director
|
7,048
-0.2%
11.68
USD 82,321
|
7,048
-0.2%
|
11.68
|
USD 82,321
|
|
